200 related articles for article (PubMed ID: 3479052)
1. [Evaluation of tumor marker CA15-3 in breast cancer].
Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of tumor markers in breast cancer patients].
Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of tumor markers in breast cancer].
Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
[TBL] [Abstract][Full Text] [Related]
5. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
Kaneko Y; Imoto S; Kasakura S
Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
[TBL] [Abstract][Full Text] [Related]
6. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
Barak V; Carlin D; Sulkes A; Treves A; Biran S
Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
[TBL] [Abstract][Full Text] [Related]
7. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
9. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
[TBL] [Abstract][Full Text] [Related]
11. [Tumor marker: practical usage of tumor marker for recurrent breast cancer--our experience].
Yoshimoto M
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2277-83. PubMed ID: 2241194
[TBL] [Abstract][Full Text] [Related]
12. [CA15-3 tumor marker in early detection of breast cancer].
Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
[TBL] [Abstract][Full Text] [Related]
13. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
14. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
16. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
18. [Tumor markers in human breast cancer].
Takami H; Shikata J
Gan To Kagaku Ryoho; 1987 Nov; 14(11):2998-3003. PubMed ID: 3479050
[TBL] [Abstract][Full Text] [Related]
19. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
Suzuki S; Nihei M; Nomizu T; Watanabe T; Kimijima I; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):1019-26. PubMed ID: 2202768
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers in gynecologic diseases].
Geyer H; Kleine W
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
